Thanks to modern imaging and molecular characterization, neuroendocrine tumours can now be detected and classified in a much more targeted manner. New therapeutic procedures such as radioligand therapy and targeted drugs are increasingly enabling individualized treatment strategies.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
- ENETS
- ENETS-certified center Inselspital Bern
- gastroenteropancreatic NET peptide receptor radionuclide therapy (PRRT)
- heterogeneous group of neoplasms
- Hormone-producing cells of the neuroendocrine system
- NET histopathological and immunohistochemical examinations
- NET localizations of the gynaecological tract
- NET precise morphological and molecular characterization
- NET somatostatin receptor expression
- NET Somatostatin receptor PET/CT
- NET Tumor Biology
- NET University Hospital Zurich
- Neuroendocrine tumors (NET)
- SeqEveRIV study
- SwissNET
You May Also Like
- Omaveloxolone for Friedreich's Ataxia
Efficacy and Safety Studied Over 6 Years
- Psoriasis: therapy with biologics and TYK-2-i
Progress assessments based on current long-term and real-world data
- Hypertension: the most important facts for daily practice
Early dual antihypertensive therapy is usually indicated
- Escitalopram for anxiety disorders
Positive effect, but no immediate improvement in symptoms
- Helicobacter pylori infection
Simplified dual therapy beats quadruple regimen
- Gastric carcinoma
Ways of precision oncology
- Endometrial Cancer
Immunological drivers and new therapeutic pathways
- Exercise for type 1 diabetes